Nav: Home

Study finds worse survival when specific thyroid cancers spread to bone

April 14, 2017

ANN ARBOR, Michigan - When cancer metastases, bone unwittingly offers a friendly place for tumor cell growth--only to have its hospitality betrayed by pathologic fractures, spinal cord compression, the need for bone surgery or irradiation, and an increased risk of death.

In the largest-known study on bone metastases in thyroid cancer, researchers at the University of Michigan Comprehensive Cancer Center found that patients with follicular and medullary thyroid cancer had the highest rate of cancer-related bone lesions and fractures and an increased risk of death.

"We know that metastases are bad. But patients in our study who had bone metastases had a worse survival rate compared to patients who had metastases at other distant sites," says Megan Haymart, M.D., assistant professor of medicine at Michigan Medicine and one of the researchers on the study. "This suggests that bone metastases are a uniquely poor prognostic indicator."

However, patients with localized or regional thyroid cancer---without metastases--have an excellent prognosis, adds Palak Choksi, M.D., assistant professor of medicine at Michigan Medicine and lead author of the study.

The Michigan Medicine study, published in the Journal of Clinical Endocrinology and Metabolism, looked at all forms of thyroid cancer--medullary, follicular, papillary, and anaplastic. The study was based on SEER-Medicare data and involved approximately 30,000 patients, 70 percent of whom were Caucasian women with an average age of 64. The high percentage of women in the study reflects the fact that thyroid cancer is three times more common in women than in men.

"Only about 8 percent of patients in the study had either a bone metastasis or skeletal-related event such as a cancer-related bone fracture," explains Haymart.

Previous studies that mainly looked at differentiated thyroid cancer and bone metastases had a significantly smaller sample size and were largely from single institutions that enrolled patients with differentiated thyroid cancers.

Currently, the data on medications for skeletal metastases in thyroid cancer has been extrapolated largely from breast cancer and other cancers that often metastasize to bone, says Choksi. Very little research has focused specifically on the use of medications to treat thyroid cancer with skeletal complications.

"Patients with thyroid cancer have been understudied," says Haymart.

This research will help tailor treatment and management, and it's especially useful for patients with high-risk thyroid cancer--medullary and follicular.

"Now that we have identified that certain thyroid cancers are at a higher risk for skeletal-related events, we can appropriately design studies looking at drugs to see which medication could prevent or effectively treat such complications," says Choksi.

"Through our study, we want other doctors to be aware that there is a higher likelihood of skeletal lesions or fractures in this high-risk population," says Choksi.

The authors acknowledge that there are limitations to the study, and the applicability of the research to younger patients is reduced. "Despite this limitation, our study parallels on a larger scale what other smaller studies have shown in a varied population group," says Choksi.

For high risk patients, future research is needed to show how to prevent and treat bone metastases. Studies have already shown that denosumab and bisphosphonates are beneficial for patients with other cancers of the bone. The researchers suspect these drugs may also be beneficial for patients with thyroid cancer and bone metastases, although additional prospective studies are need.
-end-
Additional authors: Maria Papaleontiou, Cui Guo, Francis Worden, Mousumi Banerjee

Funding: National Institutes of Health grants R01CA201198 and K08 AG049684, Agency on Healthcare Research and Quality grant R01HS024512, the Punya Foundation for Thyroid Cancer Research

Disclosure: None

Reference: Journal of Clinical Endocrinology and Metabolism, Vol. 102 Issue 4, doi: 10.1210/jc.2016-3906

Michigan Medicine - University of Michigan

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.